Exposure-Response Analysis of Etrolizumab in Patients with Moderately-to-severely Active Ulcerative Colitis ACoP12 (Nov 2021) PMX-82. Kassir N, Zhu R, Moein A, Langenhorst J, Ribbing J, Zhang R, Tang M, Oh YS, Zhang W. ConferenceImmunologyInflammationPharmacometrics Pharmetheus Affiliates Senior Director, MIDD Consultant Jurgen Langenhorst See bio Principal Director, MIDD Consultant & Senior Expert Jakob Ribbing See bio
